|||Page|| |---|---|---|---| |Report ofthe Trustees|1|to|9| |Report ofthe Independent
Auditors|10|to|12| |Statement ofFinancial Activities||13|| |Balance Sheet||14|| |Cash Flow Statement||15|| |Notes to the Cash Flow Statement||16|| |Notes to the Financial Statements|17|to|30| ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ||||||2023|2022| |---|---|---|---|---|---|---| ||||Unrestricted|Restricted|Total|Total| ||||fund|funds|funds|funds| |||Notes|||F.|| |INCOME AND ENDOWMENTS|FROM|||||| |Donations
and legacies||3|2,177,911|241,123|2,419,034|1,457,244| |Other trading
activities
Investment
income
Other income||4
5
6|1,198818
80,131
68 832||1,198,818
80,131
68,832|695,727
84,906
1 223| |Total|||3,525692|24'I,123|3,766,815|2,239,100| |EXPENDITURE ON||||||| |Raising funds||7|1,054,164||1,054,164|665,291| |Charitable
activities||||||| |Library funding||||||| |Research projects|||2,926270|53,115|29793~5|1 921,567| |Total|||3,980434|53,115|4,033,549|2,586,858| |Net gains/(losses)
on investments|||~867,5)2)||~364,5)2)|19771| |NET INCOME/(EXPENDITURE)
Transfers
between
funds||23|(816,254)
187440|188,008
~187440)|(628,246)|(327,987)| |Net movement
in funds|||(628,814)|568|(628,246)|(327,987)| |RECONCILIATION
OF FUNDS||||||| |Total funds brought
forward|||4,642,610|345,520|4,988,130|5,316,117| |TOTAL FUNDS CARRIED FORWARD|||4 013796|346,088|4 359,864|4,988,130| ## |||||2023|2022| |---|---|---|---|---|---| |||Unrestricted|Restricted|Total|Total| ||Notes|fund
f|funds
f|funds
f|fundsf| |FIXEDASSETS|||||| |Tangible assets|17|95,975||95,975|92,010| |Investments|16|4 54'1 549||4,541,549|4 865 674| |||4,637,524||4,637,524|4.957,684| |CURRENT ASSETS|||||| |Debtors|19|986,904||986,904|645,228| |Cash al bank and in hand||2 792 10?|34608S|3,138195|2,400,769| |||3,779,011|346,088|4,125,099|3,045,997| |CREDITORS|||||| |Amounts
falling due within one year|20|(548,057)||(548,057)|(486,832)| |NET CLIRRENT ASSETS||3,230954|346 088|3,577,042|2 559,165| |TOTAL ASSETSLESSCURRENT|LIABILITIES|7,868,478|346,088|&,214,566|7,516,849| |PROVISIONS FOR LIABILITIES|22|(3,854,682)||(3,854,682)|(2,528,719)| |NET ASSETS||4,013798|346,088|4 359884|4988130| |FUNDS|23||||| |Unrestricted
funds||||4,013,796|4,642,610| |Resiricted
funds||||346,088|345 520| |TOTAL FUNDS||||4 359884|4 988,130| ## |||2023|2022| |---|---|---|---| ||Notes|8|| |Cash flows from operating
activities|||| |Cash generated
from operations|a)|737416|~718514)| |Net cash provided
by/(used
in) operating|activities|737416|~718514)| |Cash flows from investing
activities|||| |Purchase
oftangible
fixed assets
Purchase offixed asset investments
Sale offixed asset investments
Interest recewed
Dividends
received||(42,734)
(1,086,474)
1,049,087
15,040
65,091|(94,753)
(1,209,223)
1,165,185
51,120
33,786| |Net cash provided
by/(used
In) investing|activities|10|~53885)| |Change
in cash and cash equivalents|in||| |the reporting
period
Cash and cash equivalents
at the||737,426|(772,399)| |beginning
ofthe reporting
period||2400769|3,173168| |Cash and cash equivatents
at the end|of||| |the reporting
period||3 138,195|2,400769| ## |a)|RECONCILIAT[ON|OF NET EXPENDITURE TO NET CASH FLOW FROM OPERATING|OF NET EXPENDITURE TO NET CASH FLOW FROM OPERATING|OF NET EXPENDITURE TO NET CASH FLOW FROM OPERATING|OF NET EXPENDITURE TO NET CASH FLOW FROM OPERATING|OF NET EXPENDITURE TO NET CASH FLOW FROM OPERATING|OF NET EXPENDITURE TO NET CASH FLOW FROM OPERATING|OF NET EXPENDITURE TO NET CASH FLOW FROM OPERATING|| |---|---|---|---|---|---|---|---|---|---| ||ACTIVITIES||||||||| |||||||||2023|2022| |||||||||E|E| ||Net expenditure
for the reporting||||period (as per the|Statement of|||| ||Financial Activities)|||||||(628,246)|(327,987)| ||Adjustments
for.||||||||| ||Depreciation
charges|||||||38,769|30,984| ||Losses/(gain)
on investments|||||||361,512|(19,771)| ||Loss on disposal offixed assets||||||||2,430| ||interest received|||||||(15,040)|(51,120)| ||Dividends
received|||||||(65,091)|(33,786)| ||Discounting
ofprovisions|||||||(66,735)|| ||Dilapidations
provision|||||||102,376|48,500| ||(increase)/decrease
Increase/(decrease)|in debtors
in creditors||||||(341,676)
1 351,547|104,030
~471794I| ||Net cash provided|by/(used||in) operations||||737416|~18 5444| |b)|ANALYSIS OF CHANGES||IN|NET|FUNDS||||| |||||||AI|1/4/22|Cash flow|At 31/3/23| ||||||||E|F|6| ||Net cash||||||||| ||Cash at bank and in|hand||||2,400769||737426|3,138195| |||||||2,400 769||737426|3,'138,195| ||Total|||||2,400,769||737,426|3,139195| ## ## ## ## ## ## ## ## ## ## ## ## |DONATIONS
|AND|LEGA|CIES||| |---|---|---|---|---|---| |||||2023|2022f| |Donations||||258,484|191,743| |Trusts||||2,600|2,550| |Legacies||||1,990,037|1,154,451| |Grants||||167,913|108,500| |||||2419,894|1457244| |Grants received, included|||In the above, are as follows;||| |||||2023f|2022| |Bristol Meyers|Squibb Pharmaceuticals||||57,500| |Public Health Wales NHS|||Trust||50,000| |Wales Cancer|Network||||1,000| |UK Government|COVID Medical Research Support Fund|||167,913|| |||||167,913|108,500| |OTHER TRADING||ACTIVITIES|||| |||||2023f|2022f| |Fundraislng||||475,820|285,126| |Retail income||||722,998|4111M1| |||||1,198,818|895,727| |INVESTMENT|INCOME||||| |||||2023|2022| |||||F|| |Income from shares||in listed companies||65,091|33,786| |Interest receivable||and simiiar income||15,040|51,120| |||||80 131|84,906| ## ## ## ||||2023
f|2022| |---|---|---|---|---| |Discounting
of provisions|||66,735|| |Insurance
claim||||| |Miscellaneous
income
Royalties|||1,797
300|53
1 170| ||||68 832|1,223| |RAISING FUNDS||||| |Raising donations
and legacies||||| ||||2023|2022| ||||f|f| |Fundraising
staff costs
Gift aid and legacy expenses
Events and general fundraising
Advertising
and publicity
Other fundraising
expenses|expenditure||224,396
11,214
86,515
12,162|208,035
8,722
7,433
2,900
37640| ||||334,287|264,730| |Other trading activities||||| ||||2023
f|2022f| |Retail staff costs
Retail purchases
Retail and warehouse
premises
Other retai( costs
Merchandise
purchases
including
Dilapidations
Depreciation
Loss on sale ofassets|costs
Christmas|cards|319,328
1,2?6
171,605
62,153
6,217
102,376
26,346|178,467
1,032
102,223
61,949
4,148
1,848
15,340
2,430| ||||689,301|367,437| ## ## ## |8.|CHARITABLE A|CTIVI|TIE|S COS|TS||||||| |---|---|---|---|---|---|---|---|---|---|---|---| |||||||||Grant|||| |||||||||funding|of||| ||||||||Direct|activities||Support|| ||||||||Costs (see|(see note||costs (see|| ||||||||note 9)
E|10)
6||note 11)
f|Totats| ||Research projects||||||166,922|2,186,327||626,136|2,979,388| |9.|DIRECT COSTS|OF CHARITABLE ACTIVITIES|||||||||| |||||||||||2023|2022| |||||||||||E|E| ||Staff costs|||||||||131,123|134,454| ||Direct cancer research||expenditure|||||||17,567|7.127| ||Science communication||costs|||||||18,232|104,723| ||Depreciation||||||||||203| |||||||||||~166922|~246 507| |10.|GRANTS PAYABLE||||||||||| |||||||||||2023|2022| ||||||||||||E| ||Research projects|||||||||2,1&6327|1,020,907| |||||||||||2,186327|1 020907| ||The total grants paid to Institutions||||during|the year|was as follows:||||| |||||||||||2023|2022| |||||||||||E|| ||Velindre
NHS Trust||||||||||124,175| ||Cardiff University|||||||||637,601|462,604| ||Swansea
University|||||||||347,813|456,674| ||Bangor University|||||||||1,130,413|6,016| ||Other adjustments|on project ciosures|||||||||(28,562)| ||Wales Cancer Network|||||||||20,000|| ||Betsi Cadwaladr|University||Health|Board|||||50,500|| |||||||||||2,186,327|1,020,907| ## ## ## ## ## ## ||||||2023
f|2022
F| |---|---|---|---|---|---|---| |Wages and salaries
Redundancy
costs
Social security costs
Pension|||||828,533
70,664
66029|674,879
8,000
52,052
55776| ||||||965,226|793 7If7| |The average|monthly|number ofemployees|during|the year was as follows:||| ||||||2023|2022| |Science 8 Policy|||||2|3| |Fundraising|||||7|6| |Retail|||||15|10| |Administration/|Governance||||5|4| ||||||29|23| |||2023|2022| |---|---|---|---| |f60,001|- f70,000|No.
1|No.| |Pension|contributions|7,465|9,236| ## ## ## |COMPARATIVES
FOR THE|COMPARATIVES
FOR THE|STATEMENT OF FINANCIAL ACTIVITIES|STATEMENT OF FINANCIAL ACTIVITIES|STATEMENT OF FINANCIAL ACTIVITIES|STATEMENT OF FINANCIAL ACTIVITIES|STATEMENT OF FINANCIAL ACTIVITIES|STATEMENT OF FINANCIAL ACTIVITIES||| |---|---|---|---|---|---|---|---|---|---| |||||||Unrestricted||Restricted|Total| ||||||||fund|funds|funds| |||||||||6|| |INCOME AND ENDOWMENTS|||FROM||||||| |Donations
and legacies||||||1,442,352||14,892|1,457,244| |Other trading
activities|||||||695,727||695,727| |Investment
income|||||||84,906||84,906| |Other income|||||||1,223||1 223| |Total||||||2,224 208||14592|2 239100| |EXPENDITURE ON|||||||||| |Raising
funds|||||||665,29'I||665,291| |Charitable
activities|||||||||| |Research projects||||||1,895,184||26 383|1,921 567| |Total||||||2,560,475||26,383|2,586658| |Net gains on investments|||||||19,771||19,771| |NET INCOME/(EXPENDITURE)||||||(316,496)||(11,491)|(327,987)| |RECONCILIATION
OF FUNDS|||||||||| |Total f'unds brought
forward||||||4,959,106||357,011|5,316,117| |TOTAL FUNDS CARRIED|FORWARD|||||4|642 610|345520|4,988,130| |FINANCIAL INSTRUMENTS|||||||||| |||||||||2023|2022| |Financial assets||||||||E|| |Financial assets that are debt||instruments||measured|al amortised|cost||4,056,266|3,019,542| |Financial assets measured|at|fair value||||||4541 549|4865674| |||||||||2023|2022| |Financlaf liabilities||||||||E|E| |Financial
liabilities measured||at amortised||cost||||524,544|392,034| |Financial
liabilities
measured||at fair value||||||3854,682|2528,719| ## |INTANGIBLE FIXEDASSETS|| |---|---| ||Compuler| ||soAware| |COST|| |At 1 April 2022 and 31 March 2023|| |AMORT(SATION|| |At 1 April 2022 and 31 March 2023|14922| |NET BOOK VALUE|| |At 31 March 2023|| ## |TANGIBLE FIXEDASSETS||||| |---|---|---|---|---| ||Leasehold|||| ||property|Fixtures|Motor|| |COST|Improvements
f|8 Equipment
6|vehicles|Totals
E| |At 1 Apnq 2022
Additions|167,398
24,052|65,963
'(8,682|20,216|253,577
42,734| |At 31 March 2023|191,450|84,645|20,2'i6|~296311| |DEPRECIATION||||| |At 1 Apri( 2022
Charge for year|111,304
~23647|30,808
14,931|19,455
191|161,567
~38769| |At 31 March 2023|~134951|~45 739|~19646|~200336| |NET BOOK VALUE||||| |At 31 March 2023|56,499|38,906|570|~95 975| |At 31 March 2022|56094|35,155|761|~92 010| ## ## ## |18.|FIXEDA|SS|ET I|NVEST|MENTS|||| |---|---|---|---|---|---|---|---|---| |||||||||Investments| ||MARKET VALUE|||||||| ||At 1 April|2022||||||4,865,674| ||Additions|||||||1,086,474| ||Disposals
Revaluations|||||||(1,049,087)
~361 5127| ||At 31 March||2023|||||4,541 549| ||NET BOOK VALUE|||||||| ||At 31 March||2023|||||4541 549| ||At 31 March||2022|||||4 865,874| ||||||||2023|2022| ||Historical|cost of||investments|||3,393,048|3,590880| ||Analysis|ofinvestments|||between funds:|||| ||||||||2023|2022| |||||||||6| ||Listed investments||||||4,508,193|4,800,481| ||UK cash|held|as part ofportfolio||||33356|65 193| ||||||||4,541,549|4,865,674| ||Cost or valuation|||at 31 March 2023 is represented||by:||| |||||||||investments| |||||||||E| ||Valuation|in 2020||||||733,672| ||Valuation|in 2021||||||756,570| ||Valuation|in 2022||||||19,771| ||Valuation|in 2023||||||(361,512)| ||Cost|||||||3.393048| |||||||||4541 549| |19.|DEBTORS:AMOUNTS||||FALLING DUE WITHIN|ONE YEAR||| ||||||||2023|2022| ||||||||f|F| ||Other debtors||||||58,803|10,362| ||Legacies|due|||||809,278|608,411| ||VAT||||||1,365|| ||Prepayments||and|accrued income|||117,458|26,455| ||||||||986,904|645,228| ## ## ||||2023|2022| |---|---|---|---|---| |||||F| |VAT payable
Project funding
payments
due
Other creditors
Accruals and deferred income|||416,671
82,199
~49 187|30,847
276,543
81,163
~98279| ||||~548057|486,832| |Included
within accruals and deferred
income
lo income received
in advance for campaigns||above is deferred
and events taking|income ofF23,515(2022:263,951).This relates
place in the next financial year.|| |lo income received
in adv|a|nce for campaigns
a|nd events taking place in the next fin|ancial year.|| |---|---|---|---|---|---| |||||2023|2022| |||||F|f| |Deferred income brought
forward
Released to SOFA
Additional
income deferred
in the year||||63,951
(63,951)
23,515|134,396
(107,500)
37500| |||||23515|63 951| |LEASING AGREEMENTS|||||| |Minimum
lease payments|under non-cancellabte||operating leases fali due as follows:||| |||||2023|2022| |||||E|| |Within one year
Between one and five years||||96,148
I60,130|102,750
215,210| |||||256,278|317,960| |PROVISIONS FOR LIABILITIES||| |---|---|---| ||2023|2022| ||f.|E| |project grant commitments
Dilapidations
provision|3,625,594
229 088|2,402,007
126712| ||3854,682|2,528,719| |||project grant| |||commitments| |||F| |Balance at 1 April 2022
New project grant commitments
Grants payable
in the year
Grant underspend
written back
Discounting
of provisions||2,402,007
2,186,327
(896,005)
~66 7357| |Balance at 31 IVlarch 2023||3,625,594| ## |MOVEMENT
IN FU|NDS||||||||| |---|---|---|---|---|---|---|---|---|---| ||||||||Net|Transfers|| ||||||||movement|between|At| |||||||At 1/4/22|in funds|funds|31/3/23| |||||||E|f|F|| |Unrestricted
funds|||||||||| |General
fund||||||4,642,610|(816,254)|187,440|4,013,796| |Restricted funds|||||||||| |Brain Tumour Scholarship||||||150,000||(150,000)|| |Eiowel Cancer Research||Fund||||61,920||(61,920)|| |Tom Walker Fund -|Acute||Myeioid||||||| |Leukaemia||||||73,617|(38,115)||35,502| |Millennium
Stadium|Charitable|||Trust||7,500|(7,500)||| |Tom Walker Fund -|Brain||Tumour|||52,483|23,210|16,980|92,673| |Nicholas Roe - Leukaemia|||Project||||50,000||50,000| |UK Government
COVID||Medicat|||Research||||| |Support Fund
Waterloo Foundation|||||||167,913
~500)|7,500|167,913| |||||||345,520|188,008|~)87,440)|346 088| |TOTAL FUNDS||||||4,986'130|~628,246)||4 359884| |Net movement
in funds,||included|||in the above are as follows:||||| |||||||Incoming|Resources|Gains and|Movement| |||||||resources|expended|losses|in funds| |||||||||8|| |Unrestricted
funds|||||||||| |General
fund||||||3,525,692|(3,980,434)|(361,512)|(816,254)| |Restricted funds|||||||||| |Tom Walker Fund -|Acute||Myeloid||||||| |Leukaemia|||||||(38,115)||(38,115)| |Millennium
Stadium|Charitable|||Trust|||(7,500)||(7,500)| |Tom Walker Fund -|Brain||Tumour|||23,210|||23,210| |Nicholas Roe - Leukaemia|||Project|||50,000|||50,000| |UK Government
COVID||Medical Research|||||||| |Support Fund
Waterloo Foundation||||||167,913|~7500)||167,913
~7500)| |||||||24'1,123|~63115)||158008| |TOTALFUNDS||||||3,766,815|~4033 549)|~361,512)|~628 246)| ## ## ## ## ## ## ## ## ## ## ##